Enzo Biochem (NYSE:ENZ) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note published on Saturday morning. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Performance

Shares of NYSE ENZ opened at $0.98 on Friday. Enzo Biochem has a 12 month low of $0.93 and a 12 month high of $1.50. The company has a 50 day simple moving average of $1.12 and a two-hundred day simple moving average of $1.12.

Enzo Biochem Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 15th will be issued a dividend of $0.10 per share. This represents a $0.40 annualized dividend and a dividend yield of 41.03%. The ex-dividend date is Friday, November 15th.

Institutional Investors Weigh In On Enzo Biochem

Institutional investors have recently modified their holdings of the business. Geode Capital Management LLC grew its position in shares of Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after purchasing an additional 11,742 shares during the period. XTX Topco Ltd lifted its position in Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after buying an additional 13,735 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Enzo Biochem by 2.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after acquiring an additional 64,417 shares during the last quarter. Finally, BBR Partners LLC purchased a new position in Enzo Biochem during the third quarter worth about $112,000. 36.90% of the stock is currently owned by institutional investors and hedge funds.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.